DigestRedComo funciona
Red
/
Empresas
AC
No verificado

AC Immune SA

Sobre qué escribimos

Anuncios brevesBiotecnologíaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

24 Comunicados de prensa

Ver todos los comunicados de prensa
30/04/2026
Biotecnología
Gestión empresarial/Administración de Empresas
AC Immune First Quarter 2026 Financial and Corporate Updates
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
30/04/2026
Biotecnología
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
07/04/2026
Biotecnología
Finanzas
Gestión empresarial/Administración de Empresas
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
19/03/2026
Biotecnología
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
13/03/2026
Biotecnología
Gestión empresarial/Administración de Empresas
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
05/03/2026
Biotecnología
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
24/02/2026
Biotecnología
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
11/12/2025
Biotecnología
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
11/11/2025
Biotecnología
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
04/11/2025
Biotecnología
Gestión empresarial/Administración de Empresas
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0